Gilead Sciences, Inc.

Isis Pharmaceuticals, Inc.

Carlsbad

Kuei-Ying Lin

Mark D Matteucci

Richard L Mackman

Lijun Zhang

Adrian S Ray

Constantine G Boojamra

David Y Markevitch

Robert J Jones

Oleg V Petrakovsky

Sundaramoorthi Swaminathan

Norbert W Bischofberger

Choung U Kim

Hyung-Jung Pyun

William A Lee

James Ming Chen

David A Oare

Maria Fardis

Xiaowu Chen

William John Watkins

Lawrence R McGee

Aesop Cho

Peter H Nelson

Jennifer R Zhang

Thorsten A Kirschberg

Lee Shun Chong

Carina E Cannizzaro

Ernest J Prisbe

Alan X Huang

Murty N Arimilli

Christopher P Lee

Michael S Louie

Mark D Mattuecci

Haolun Jin

Chris A Buhr

Kenneth C Cundy

Rick Wagner

Steven H Krawczyk

Ralph F Hirschmann

Vidya K Prasad

Rosemarie Sherlock

Craig S Gibbs

Jason G Lewis

Richard W Wagner

Ken Kent

Matthew A Williams

Manoj C Desai

Zheng-Yu Yang

Michael L Mitchell

Lianhong Xu

Hongtao Liu

Oliver L Saunders

Robert Anthony Mook

Jason K Perry

Randolph B DePrince

Gong-Xin He

Jianying Wang

Richard Yu

Mark L Sparacino

Jiancun Zhang

Bob Jones

James D Tario

Murty N Arimili

George S Lewis

Kevin L Facchine

Mark M Becker

Azar Dastgah

Tanisha D Rowe

Mark Sparacino

Richard H Yu

Lawwrence R Mcgee

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Phosphonate analogs of HIV inhibitor compounds

Antiviral compounds

A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Phosphonate inhibitors of HCV

Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds

The invention is related to phosphorus substituted therapeutic agents, compositions containing such phosphorus substituted agents, and therapeutic methods that include the administration of such phosphorus substituted agents, as well as to processes and intermediates useful for preparing such agents.

Therapeutic phosphonate compounds

Compounds having structure (1) wherein Ris &#x2014;H a protecting group, a linker or a binding partner; and Rand Rare as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.

Pyrimidine derivatives for labeled binding partners

The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Anti-cancer phosphonate analogs

Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.

Nucleotide analogs

The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Anti-inflammatory phosphonate compounds

Compounds having structure (1)wherein Ris &#x2014;H a protecting group, a linker or a binding partner; and Rand Rare as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.

Pyrimidine derivatives and oligonucleotides containing same

Compounds having particular interest as labels and various novel uses in diagnostics and therapeutics are provided which have structure (1)wherein Ris a binding partner, a linker or H; Also provided are novel intermediates and methods for the preparation and use of the structure (1) compounds.

Growing community of inventors

Fremont, CA, United States of America

Kuei-Ying Lin